Other investors in the round included Gemma Frisius Fund, which is the spin-off fund of the University of Leuven, and Flemish investment company PMV.
The company said it will use the funds to finance clinical studies in Europe and the US to validate its Encage technology for the focal treatment of prostate cancer.
TROD also said that it has relocated its head office to Leuven, Belgium and signed a collaboration agreement with the Medical Imaging Research Center in the University Hospitals Leuven.
Capricorn partner Frank Bulens said, “This transaction is a great example of how a number of local actors can make the difference: the involvement of a strong local investor syndicate and the input of local know-how and expertise will allow TROD Medical to advance and optimize its product offer.
“We are very happy that we identified this opportunity back in 2012 and that we could convince the founders and CEO to move to Flanders. The technology is great and very promising.”
Other companies backed by Capricorn include Belgian cloud-based digital video recorder maker Right Brain Interactive, which raised a €6m round in July this year.
Copyright © 2013 AltAssets